Projets stratégiques et opérationnels - Pharma/Biotech

2017 - NOW : PARTNER - TALOS HEALTH SOLUTIONS /FRANCE

• Talos Health Solutions is a consultancy company that drives digital marketing and communication events directed towards healthcare professionals and patients, using a proprietary digital platform,
• Worked with various Medical Societies and Patient Advocacy Groups to organize and implement a dozen events in Europe, the US and Africa, covering several medical conditions, including Asthma, Oncology, COPD, Renal Deficiency, Auto-immune diseases, Diabetes, HIV, STDs.

2020 - APRIL 2021 : CEO - APTAMIR THERAPEUTICS, INC./ FRANCE

• AptamiR is a Biotech Company developing breakthrough therapies to treat Obesity and related Cardio-Metabolic disorders through increasing Energy Expenditure, by inducing Adipocyte Browning,
• Structured the Business plan for the company, and led fundraising activities with VCs and Pharma companies.

2014 - 2016 : HEALTHCARE CONSULTING /NORTH AFRICA

• Drove consulting projects with local pharmaceutical companies in business planning, product launch, sales force training, and KOL management strategies,
  • Worked with GlaxoSmithKline on product portfolio prioritization and out-licensing for mature brands (ex UCB), within North Africa,
  • Drove the restructuring of customer targeting and sales force allocation, and implemented “selling skills” and product training programs for sales representatives.

• Member of the Regional Management team,
• Managed 15 marketers for sales of €120M,
• Led the regional launch of 2 new products, and managed the go-to-market strategy for 4 others,
• Implemented a product portfolio prioritization strategy that led to 20% savings in the marketing budget.

2010 - 2011 : Director, Business Development/ Eastern & Central Europe/ Belgium

• Member of the Management Team,
• Reported to the Senior VP, and led business development activities across the region (15 countries):
  • Led the development of business cases and presentations to the COMEX team,
  • Implemented a formal business development processes in the region, and led negotiations and due diligence,
  • Closed 2 co-promotion deals of €10M value in Austria and Romania.

2010 : General Manager/ Romania

• Managed a team of 35 people for sales of €25M,
• Drove the audit of the business, ensured business continuity in crisis situation, led negotiations with distributors and wholesalers to resume collaboration, and built a new 2009 P&L estimate and 2010 budget for the affiliate.

2009 - 2010 : General Manager/ North Africa

• Member or the management team for the Middle East & Africa,
• Managed distributors across Algeria, Morocco and Tunisia,
• Managed a business of €17M and 80 people,
• Implemented a business restructuring plan that enhanced performance :
  • Aligned regulatory and supply chain processes to optimize product flow,
  • Setup an 18-month rolling product forecast, and set accountability locally,
  • Implemented a Sales Force Effectiveness plan to increase targeting of specialists,
  • Launched Keppra for Epilepsy in Algeria,
• Increased 2008 sales by more than 30%, and led the transfer of the business to GSK.

2006 - 2009 : Director, Global New Product Marketing/ Belgium

• Developed product profiles and valuation for biological (antibody) products in early clinical development within the inflammation and Osteoporosis franchise, and ensured proper commercial input is taken into account in the design and implementation of clinical studies.
• Led the development of the Inflammation franchise strategy, obtained approval by the COMEX, and led implementation through prioritization of R&D programs.
• Managed the partnership with Amgen for the development of Evenity, and drove commercial assessment of various target indications.

Molecular Diagnostics, Belgium

• Reported to the COO, and was member of the Executive team,
• Worked with the Boston Consulting Group to develop the corporate strategic plan, conducted financial analyses for M&A and divestment opportunities, and was part of the team that raised equity of €34,5M.

o Managed a team of two medical representatives for sales of €4M,

o Launched Stocrin (Efavirenz) for the treatment of HIV infection, and achieved sales growth of 30% year-overyear in a very competitive market,

o Drove annual awareness campaigns in collaboration with Belgian HIV patient organizations,

2002 - 2004 : Manager Sales & Marketing/ Belgium

• Managed a team of two medical representatives for sales of €4M,
• Launched Stocrin (Efavirenz) for the treatment of HIV infection, and achieved sales growth of 30% year-overyear in a very competitive market,
• Drove annual awareness campaigns in collaboration with Belgian HIV patient organizations

1994 - 2000 : Manager R&D/ USA

• Led pre-clinical testing for 2 major drug candidates for the treatment of osteoporosis,
• Established R&D partnerships with academic laboratories,
• Submitted three patent applications, published 10 articles in peer-reviewed journals,
• Received the "Young Investigator Award" from the American Society for Bone and Mineral Research.